Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the a

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared t

 The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP)

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-m